inspirator schreef op 28 maart 2018 18:54:
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
Mark GenoveseEmail author, Rene Westhovens, Luc Meuleners, Annegret Van der Aa, Pille Harrison, Chantal Tasset and Arthur Kavanaugh
Arthritis Research & Therapy201820:5
-z© The Author(s). 2018
Received: 28 November 2017Accepted: 8 February 2018Published: 23 March 2018
Conclusions
Filgotinib as MTX add-on therapy or as monotherapy demonstrated rapid and sustained (to 24 weeks) improvements in health-related quality of life and functional status in patients with active RA.
arthritis-research.biomedcentral.com/...